Abstract. Mechanisms underlying bradykinin-induced vasoconstriction were investigated in rat perfused mesenteric vascular beds with active tone. In preparations with intact endothelium, bolus injections of bradykinin (1 to 1,000 pmol) dose-dependently produced three-phase vascular effects, which consisted of a first-phase vasodilation followed by a second-phase vasoconstriction and a subsequent third-phase vasodilation; these effects were abolished by FR172357 (bradykinin B 2 -receptor antagonist), but not by des-Arg 9 -[Leu 8 ]-bradykinin (bradykinin B 1 -receptor antagonist). In preparations with intact endothelium, indomethacin (cyclooxygenase inhibitor), seratrodast (thromboxane A 2 (TXA 2 )-receptor antagonist), ONO-3708 (TXA 2 / prostaglandin H 2 (PGH 2 )-receptor antagonist) or ozagrel (TXA 2 synthesis inhibitor) markedly inhibited the bradykinin-induced vasoconstriction. In preparations without endothelium, the bradykinin-induced vasoconstriction was abolished by indomethacin and ONO-3708, while seratrodast and ozagrel had no effect. These results suggest that the endothelium-dependent vasoconstriction of bradykinin is mainly mediated by TXA 2 and that prostanoids other than TXA 2 , probably PGH 2 , in mesenteric vascular smooth muscle are responsible for bradykinin-induced endothelium-independent vasoconstriction.
Introduction
Bradykinin is a potent endogenous vasoactive stimulant, mediating both vasodilation and vasoconstriction (1 -3) . Bradykinin produces vascular action via authentic receptors, the B 1 and B 2 subtypes, in endothelial and smooth muscle cells (4 -7) . The mechanisms underlying the vasoconstrictions depend on the tissues and the species studied (2, 8, 9) . Several studies reported that the cyclooxygenase products, prostaglandin (PG) H 2 (PGH 2 ), thromboxane A 2 (TXA 2 ), and PGF 2a , mediate the contraction evoked by the peptide (10 -12) . Although the vasorelaxant effect of bradykinin is well known to be endothelium-and nitric oxide (NO)-dependent (3, 7, 13) , the nature and role of its vasoconstrictor effect is unclear.
We previously reported that exogenous bradykinin in the rat mesenteric resistance artery induces triphasic vascular responses, which consisted of an initial phase vasodilation followed by a second-phase vasoconstriction and a third-phase gradual vasodilation (14) . We also suggested that the arachidonic acid metabolite, probably TXA 2 , in the mesenteric artery was responsible for the vasoconstrictor response to bradykinin (14) . However, the role of prostanoids in bradykinin-induced vasoconstrictor responses of the mesenteric resistance artery remains unknown. The present study was, therefore, designed to investigate precise mechanisms underlying bradykinin-induced vasoconstriction in rat mesenteric resistance arteries.
Materials and Methods

Animals
Male Wistar rats, weighing 220 to 350 g, were used in the present study. Animals were given food and water ad libitum. They were housed in the Animal Research Center of Okayama University at a controlled ambient temperature of 22 ± 2°C with 50 ± 10% relative humidity and with a 12-h light / 12-h dark cycle (lights on at 8:00 a.m.).
Perfusion of mesenteric vascular beds
The animals were anesthetized with pentobarbital-Na (50 mg / kg, intraperitoneally) and the mesenteric vascular beds were isolated and prepared for perfusion as described previously (14, 15) . The superior mesenteric artery was cannulated and flushed gently with KrebsRinger bicarbonate solution (Krebs solution) to eliminate blood in the vascular bed. After removal of the entire intestine and associated vascular bed, the mesenteric vascular bed was separated from the intestine by cutting close to the intestinal wall. Only four main arterial branches from the superior mesenteric trunk running to the terminal ileum were perfused. All other branches of the superior mesenteric artery were tied off. The isolated mesenteric vascular bed was then placed in a water-jacketed organ bath maintained at 37°C and perfused with a modified (see below) Krebs solution at a constant flow rate of 5 mL / min with a peristaltic pump (model AC-2120; ATTO Co., Tokyo). Preparations were also superfused with the same solution at a rate of 0.5 mL / min to prevent drying. The Krebs solution was bubbled with a mixture of 95% O 2 -5% CO 2 before passage through a warming coil maintained at 37°C. Modified Krebs solution was of the following composition: 119.0 mM NaCl, 4.7 mM KCl, 2.4 mM CaCl 2 , 1.2 mM MgSO 4 , 25.0 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 0.03 mM disodium EDTA, and 11.1 mM dextrose (pH 7.4). Changes in the perfusion pressure were measured with a pressure transducer (model TP-400T; Nihon Kohden, Tokyo) and recorded using a pen recorder (model U-228; Nippon Denshi Kagaku, Tokyo).
Chemical removal of vascular endothelium
To remove the vascular endothelium, preparations with resting tone were perfused with a 1.80 mg / mL solution of sodium deoxycholate (SD) in saline for 30 s. This caused a transient increase (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) in perfusion pressure. Then, the preparations were rinsed with SD-free Krebs solution for 40 min. After the preparations were contracted by perfusion with Krebs solution containing methoxamine, chemical removal of the endothelium was assessed by the lack of a relaxant effect after a bolus injection of 1 nmol acetylcholine (ACh), which was injected directly into the perfusate proximal to the arterial cannula with an injection pump (model 975; Harvard Apparatus, Holliston, MA, USA). Injection volumes were 100 mL for 12 s.
Experimental protocols
Isolated mesenteric vascular beds were perfused with Krebs solution, and perfusion pressure was increased by perfusion with Krebs solution containing the a 1 -adrenoceptor agonist methoxamine (7 mM) in the presence of guanethidine (5 m M) that was added to exclude possible involvement of vascular adrenergic nerves by blocking adrenergic neurotransmission. After the elevated perfusion pressure stabilized, bradykinin at doses of 1, 3, 10, 30, 100, 300, and 1,000 pmol were directly injected into the perfusate using the injection pump. Injection volumes were 100 m l for 12 s. To assess the mechanisms underlying the vascular effect of bradykinin, bolus injections of bradykinin were performed in preparations with intact endothelium during perfusion of the bradykinin B 1 -receptor antagonist des-Arg (19) .
To assess the influence of endothelium, the bradykinin-induced vascular responses were examined in preparations with chemical removal of the endothelium by SD. After SD perfusion, the active tone of the preparation was produced by perfusion with Krebs solution containing methoxamine and guanethidine (5 mM). The concentration of methoxamine was reduced to 2 mM from 7 m M because the vasoconstrictor response was enhanced after endothelium removal. After confirming successful removal of the endothelium by the lack of a relaxant effect with 1 nmol ACh injection, bradykinin injections were carried out. In preparations without endothelium, bradykinin injections were performed during perfusion of Krebs solution containing indomethacin (0.5 mM), seratrodast (5 m M), ozagrel (100 mM), or ONO-3708 (10 mM), and methoxamine and guanethidine.
At the end of each experiment, preparations were perfused with 100 mM papaverine to cause complete relaxation. Vasodilator activity is expressed as percentage of the perfusion pressure at maximum relaxation induced by papaverine. Vasoconstrictor activity is expressed as percentage of the perfusion pressure before the bradykinin injection.
Statistical analyses
Experimental results are presented as the means ± S.E.M. Statistical analysis was evaluated by Tukey's multiple comparison test. Values of P<0.05 were considered to indicate statistical significance.
Drugs
The following drugs were used: ACh chloride (Daiichi Pharmaceutical Co., Tokyo); bradykinin and des-Arg 
Results
Vascular effect of bradykinin in rat perfused mesenteric arteries with endothelium
As shown in Fig. 1 , a bolus injection of ACh in the mesenteric vascular bed with active tone caused a sharp decrease in perfusion pressure due to vasodilation, which is mediated by intact endothelium (20) . In this preparation, as shown in Fig. 1 , bolus injections of bradykinin (1 to 1,000 pmol) caused triphasic vascular responses: the first-phase was an initial short and sharp fall in perfusion pressure due to vasodilation followed by a second-phase transient increase in perfusion pressure due to vasoconstriction; and this was then followed by the third-phase gradual decrease in perfusion pressure due to vasodilation. As shown in Fig. 2 , the bradykinin B 1 -receptor antagonist des-Arg 9 -[Leu 8 ]-bradykinin (1 mM) had no effect on the bradykinin-induced second-phase vasoconstriction. However, as shown in Fig. 2 , the bradykinin B 2 -receptor antagonist FR172357 (0.1 mM) abolished vasoconstrictor responses to bolus injections of bradykinin.
Effect of indomethacin, seratrodast, ONO-3708, or ozagrel treatment on vascular responses to bolus injections of bradykinin in rat perfused mesenteric arteries with endothelium
As shown in Figs. 3 and 4 , treatment with indomethacin (0.05 and 0.5 mM) (Fig. 3A) , ozagrel (10 and 100 m M) (Fig. 3B) , ONO-3708 (5 and 10 m M) (Fig. 4A) , or seratrodast (0.5 and 5 m M) (Fig. 4B) significantly inhibited the second-phase vasoconstriction in response to bradykinin injection in a concentration-dependent manner.
Effect of indomethacin, ONO-3708, seratrodast, or ozagrel treatment on vascular responses to bolus injections of bradykinin in rat perfused mesenteric arteries without endothelium
Treatment of the perfused mesenteric vascular bed with SD abolished the ACh-induced vasodilation, indicating successful removal of the endothelium.
In preparations without endothelium, indomethacin (0.5 m M) (Fig. 5) and ONO-3708 (10 m M) (Fig. 5 ) markedly inhibited the second-phase vasoconstriction induced by bradykinin injections.
However, as shown in Fig. 5 , in preparations without endothelium, neither seratrodast (5 m M) nor ozagrel (100 mM) showed an effect on the second-phase vasoconstriction induced by bradykinin injections.
Discussion
The present study demonstrated that exogenous bradykinin in the rat mesenteric artery induced dosedependent vascular responses, which consisted of three phases: an initial sharp vasodilation followed by a second transient vasoconstriction and a subsequent third gradual vasodilation. These vascular responses to bradykinin injections were abolished by the bradykinin B 2 -receptor antagonist FR172357 (16) , whereas the bradykinin B 1 -receptor antagonist Des-Arg
]-bradykinin had no effect. In the previous report, we showed that the bradykinin B 1 -receptor agonist DesArg 9 -bradykinin induced no vascular response in the rat mesenteric artery (14) . Thus, it is very likely that the triphasic response to bradykinin injection was mediated by bradykinin B 2 receptors. These results are in line with those reported in the rat and rabbit arteries (12, 14, 21) .
In the preparation with intact endothelium, treatment with indomethacin (cyclooxygenase inhibitor), seratrodast (TXA 2 -receptor antagonist), ONO-3708 (TXA 2 / PGH 2 -receptor antagonist), or ozagrel (TXA 2 synthase inhibitor) markedly inhibited the second-phase vasoconstriction in response to bradykinin injection. These results clearly suggest that arachidonic acid metabolites, probably TXA 2 and related products, are responsible for the second-phase vasoconstriction induced by bradykinin. However, in mesenteric arteries without endothelium, neither seratrodast nor ozagrel showed an effect on the second-phase vasoconstriction induced by bradykinin. TXA 2 has been shown to be released from endothelial cells (22, 23) . Thus, it is likely that bradykinin stimulates TXA 2 release mainly in the presence of intact endothelium to cause vasoconstriction. This also suggests that TXA 2 is released from endothelium but not from vascular smooth muscle cells when bradykinin B 2 receptors are stimulated.
In contrast, indomethacin abolished the bradykinininduced second-phase vasoconstriction even in the mesenteric artery without endothelium. This finding suggests that prostanoids other than TXA 2 are involved in the bradykinin-induced vasoconstriction in the denuded mesenteric artery. In the present study, treatment with ONO-3708, which blocks TXA 2 / PGH 2 receptors, markedly inhibited the bradykinin-induced vasoconstriction. Thus, this finding strongly suggests that PGH 2 is responsible for the bradykinin-induced endotheliumindependent vasoconstriction in the rat mesenteric artery. Bradykinin has been shown to cause vasoconstriction (10, 24, 25) . The bradykinin-induced vasoconstrictor response has been reported to be endothelium-independent and indomethacin-sensitive or mediated by bradykinin B 2 receptors located in the vascular smooth-muscle layer (2, 9) . In addition, other studies have shown that the action of bradykinin was largely dependent on stimulation of the cyclooxygenase pathway to produce PGH 2 and possibly TXA 2 , which can activate smooth muscle TXA 2 / PGH 2 receptors to elicit vasoconstriction (10, 11) . However, the bradykinin-induced vasoconstriction in the canine isolated saphenous vein without endothelium was potentiated by indomethacin (26) . Therefore, involvement of prostanoids in bradykinin-induced endothelium-independent vasoconstriction may be species and tissue-dependent (2, 9) .
From these results, it is concluded that bradykinin stimulates TXA 2 release from endothelium and PGH 2 release from vascular smooth muscle cells to cause endothelium-dependent and independent vasoconstriction in the rat mesenteric resistance artery, respectively. The present study suggests that mechanisms underlying bradykinin-induced vasoconstriction are different in the artery with or without the endothelium and that the characteristics of TXA 2 / PGH 2 receptors in the endothelium may be different from those of the receptors in rat mesenteric vascular smooth muscle.
